Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 23-30

  Potier, Louis ^a,b,c,d   Waeckel, Ludovic ^a,b,c   Vincent, Marie Pascale ^a,b,c   Chollet, Catherine ^a,b,c   Gobeil, Fernand ^e   Marre, Michel ^c,d,f   Bruneval, Patrick ^g   Richer, Christine ^a,b,c   Roussel, Ronan ^a,b,c,d,f   Alhenc Gelas, François ^a,b,c   Bouby, Nadine ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ DE SHERBROOKE   (Canada)

^f INSERM   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; GLYCOGEN SYNTHASE KINASE 3BETA; ICATIBANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAMIPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84879321057     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203927     Document Type: Article

References (53)

1. Alhenc-Gelas F., Bouby N, Richer C., Potier L, Roussel R, and Marre M (2011) Kinins as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des 17: 2654-2662.
2. Bélanger S., Bovenzi V, Côté J, Neugebauer W, Amblard M, Martinez J, Lammek B, Savard M, and Gobeil F, Jr (2009) Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 30:777-787.
3. Bell RM and Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185-193.
4. Bodin S, Chollet C, Goncalves-Mendes N, Gardes J., Pean F, Heudes D, Bruneval P., Marre M, Alhenc-Gelas F, and Bouby N (2009) Kallikrein protects against micro-albuminuria in experimental type I diabetes. Kidney Int 76:395-403.
5. Bouhidel O, Pons S, Souktani R., Zini R, Berdeaux A, and Ghaleh B (2008) Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 295:H1580-H1586.
6. Brown NJ, Gainer JV, Murphey L.J., and Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102:2190-2196.
7. Chahine R, Adam A, Yamaguchi N., Gaspo R, Regoli D, and Nadeau R (1993) Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol 108:318-322.
8. Côté J, Savard M, Bovenzi V, Bélanger S, Morin J, Neugebauer W, Larouche A, Dubuc C, and Gobeil F, Jr (2009) Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides 30:788-795.
9. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, and Ezzati M (2006) Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368:1651-1659.
10. Di Filippo C., Marfella R, Cuzzocrea S., Piegari E, Petronella P, Giugliano D., Rossi F, and D'Amico M (2005) Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ische-mia/reperfusion. Diabetes 54:803-810.
11. Donahoe SM, Stewart GC, McCabe C.H., Mohanavelu S., Murphy SA, Cannon CP, and Antman EM (2007) Diabetes and mortality following acute coronary syndromes. JAMA 298:765-775.
12. Duckworth W, Abraira C, Moritz T., Reda D, Emanuele N, Reaven P.D., Zieve FJ, Marks J, Davis SN, and Hayward R, et al; VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139.
13. Furchgott RF and Vanhoutte PM (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3:2007-2018.
14. Gerczuk PZ and Kloner RA (2012) An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 59:969-978.
15. Gougat J, Ferrari B, Sarran L., Planchenault C, Poncelet M, Maruani J., Alonso R, Cudennec A, Croci T., and Guagnini F, et al (2004) SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl] amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl) -N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309:661-669.
16. Griol-Charhbili V., Messadi-Laribi E, Bascands J.L., Heudes D., Meneton P, Giudicelli JF, Alhenc-Gelas F, and Richer C (2005) Role of tissue kallikrein in the car-dioprotective effects of ischemic and pharmacological preconditioning in myocar-dial ischemia. FASEB J 19:1172-1174.
17. Gross ER and Gross GJ (2006) Ligand triggers of classical preconditioning and postconditioning. Cardiovasc Res 70:212-221.
18. Gross ER, Hsu AK, and Gross GJ (2007) Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56:127-136.
19. Hausenloy DJ and Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448-460.
20. Hock FJ, Wirth K, Albus U., Linz W, Gerhards HJ, Wiemer G, Henke S., Breipohl G, König W, and Knolle J, et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769-773.
21. Ishihara M, Inoue I, Kawagoe T., Shimatani Y, Kurisu S, Nishioka K., Kouno Y, Umemura T, Nakamura S., and Sato H (2001) Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38:1007-1011.
22. Juhaszova M, Zorov DB, Kim S.H., Pepe S., Fu Q, Fishbein KW, Ziman B.D., Wang S., Ytrehus K, and Antos CL, et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535-1549.
23. Kakoki M, McGarrah RW, Kim H.S., and Smithies O (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104:7576-7581.
24. Kannel WB and McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8-13.
25. Lagneux C, Bader M, Pesquero J.B., Demenge P., and Ribuot C (2002) Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2:815-822.
26. Leeb-Lundberg L.M., Marceau F, Müller-Esterl W, Pettibone DJ, and Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77.
27. Linz W, Wiemer G, and Schölkens BA (1996) Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes 45 (suppl 1):S51-S58.
28. Liu Y, Thornton JD, Cohen M.V., Downey JM, and Schaffer SW (1993) Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88:1273-1278.
29. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
30. Marfella R, Di Filippo C, Esposito K, Nappo F., Piegari E, Cuzzocrea S, Berrino L., Rossi F, Giugliano D, and D'Amico M (2004) Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 53:454-462.
31. Meneton P, Bloch-Faure M, Hagege A.A., Ruetten H., Huang W, Bergaya S, Ceiler D., Gehring D, Martins I, and Salmon G, et al (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98:2634-2639.
32. Messadi E, Vincent MP, Griol-Charhbili V, Mandet C., Colucci J, Krege JH, Bruneval P, Bouby N., Smithies O, and Alhenc-Gelas F, et al (2010) Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J 24:4691-4700.
33. Messadi-Laribi E., Griol-Charhbili V, Pizard A., Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, and Richer C (2007) Tissue kallikrein is involved in the car-dioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 323:210-216.
34. Miki T, Miura T, Hotta H., Tanno M, Yano T, Sato T., Terashima Y, Takada A, Ishikawa S., and Shimamoto K (2009) Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 58:2863-2872.
35. Miki T, Itoh T, Sunaga D., and Miura T (2012) Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 11:67.
36. Mozaffari MS and Schaffer SW (2003) Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury. Hypertension 42:1042-1049.
37. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy D.J., Heusch G., Vinten-Johansen J, Yellon DM, and Schulz R; Working Group of Cellular Biology of Heart of European Society of Cardiology (2010) Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87:406-423.
38. Patel A, MacMahon S, Chalmers J., Neal B, Billot L, Woodward M., Marre M, Cooper M, Glasziou P., and Grobbee D, et al; ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572.
39. Penna C, Mancardi D, Rastaldo R., Losano G, and Pagliaro P (2007) Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 75: 168-177.
40. Piot C, Croisille P, Staat P., Thibault H, Rioufol G, Mewton N., Elbelghiti R, Cung TT, Bonnefoy E, and Angoulvant D, et al (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473-481.
41. Roubille F, Franck-Miclo A, Covinhes A., Lafont C, Cransac F, Combes S., Vincent A, Fontanaud P, Sportouch-Dukhan C, and Redt-Clouet C, et al (2011) Delayed postconditioning in the mouse heart in vivo. Circulation 124:1330-1336.
42. Spillmann F, Van Linthout S, Schultheiss HP, and Tschöpe C (2006) Car-dioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Curr Opin Nephrol Hypertens 15:22-29.
43. Tsang A, Hausenloy DJ, Mocanu M.M., Carr RD, and Yellon DM (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54:2360-2364.
44. Westermann D, Walther T, Savvatis K., Escher F, Sobirey M, Riad A., Bader M, Schultheiss HP, and Tschöpe C (2009) Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58:1373-1381.
45. White HD and Chew DP (2008) Acute myocardial infarction. Lancet 372:570-584.
46. Xi L, Das A, Zhao Z.Q., Merino VF, Bader M, and Kukreja RC (2008) Loss of myo-cardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 118(14, suppl)S32-S37.
47. Yang XM, Krieg T, Cui L., Downey JM, and Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36:411-421.
48. Yang XP, Liu YH, Scicli G.M., Webb CR, and Carretero OA (1997) Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30:735-740.
49. Yellon DM and Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1135.
50. Yin H, Chao J, Bader M., and Chao L (2007) Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 28: 1383-1389.
51. Yoshida H, Zhang JJ, Chao L, and Chao J (2000) Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35:25-31.
52. Zhao ZQ, Corvera JS, Halkos M.E., Kerendi F., Wang NP, Guyton RA, and Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579-H588.
53. Zhu SG, Xi L, and Kukreja RC (2012) Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic post-conditioning in vivo: potential role for Hsp20, F1-ATPase d and Echs1. J Cell Mol Med 16:950-958. Médicale